Esther Guevara Sanginés

Esther Guevara Sanginés

Auto-generated profile, based on publicly available information

Esther Guevara Sanginés

Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2018 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
CRCatalina Rincón-Pérez
Catalina Rincón-Pérez
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
MFMarco Antonio Figueroa-Morales
Marco Antonio Figueroa-Morales
JLJorge Luna-Pech
Jorge Luna-Pech
LGLinda García-Hidalgo
Linda García-Hidalgo
JMJosé Luis Mayorga-Butrón
José Luis Mayorga-Butrón
Background: The diagnostic approaches and therapeutic strategies of atopic dermatitis (AD) are generally inconsistent among physicians and health institutions.Objective: To develop a consensus statement among experts to reduce the variations in practice regarding the diagnosis and treatment of patients ≥ 12 years with AD to improve their care.Methods: Systematic literature search in PubMed and GREAT. With methodological support and using the Delphi method, a formal consensus was developed among 16 experts in Dermatology and Allergology, based on the current evidence and its applicability in the Mexican context. Apart from intense electronic communication, several issues of disagreement were discussed in two face-to-face meetings.Results: The clinical experts reached consensus on 46 statements related to the definition, classification, diagnostic strategies and treatment of AD. For the diagnosis we suggest the Williams criteria and for severity scoring the SCORAD (by the doctor) and POEM (by the patient). In addition to general care and treatment education (workshops), we suggest four steps for treatment, depending on severity: 1. Topical treatment with anti-inflammatory agents (and systemic: antihistamines/antileukotrienes —low level evidence—) 2. Phototherapy, 3. Cyclosporin A and 4. Dupilumab, with the possibility of managing this biological earlier on if a fast effect is needed. In extrinsic AD we suggest evaluating the addition of allergen immunotherapy or an elimination diet, if there is an IgE-mediated respiratory or food allergy, respectively.Conclusion: The panel of experts reached consensus on relevant aspects of AD with a focus on the transcultural adaptation of recent evidence.

6 August 2024 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
ENElsy Maureen Navarrete-Rodríguez
Elsy Maureen Navarrete-Rodríguez
CSCentro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
Centro de Excelencia en Asma y Alergia Erlinda Larenas S.C.
HCHelena Vidaurri de la Cruz
Helena Vidaurri de la Cruz
JLJorge A. Luna-Pech
Jorge A. Luna-Pech
ESEsther Guevara Sanginés
Esther Guevara Sanginés

29 April 2020 in Revista Alergia México
Verified
Journal Article
Open access
PDF file
EGEsther Guevara-Sanginés
Esther Guevara-Sanginés
DPDiego Pérez-Rojas
Diego Pérez-Rojas
ASArmando Nevárez Sida
Armando Nevárez Sida
MAMartha Alicia Aceves
Martha Alicia Aceves
MBMaría Teresa Barrón-Tapia
María Teresa Barrón-Tapia
LELorena Estrada-Aguilar
Lorena Estrada-Aguilar
Background: In Mexico, the economic burden of medical care for patients with atopic dermatitis is unknown.Objective: To determine the annual direct medical costs of the treatment for patients with moderate to severe atopic dermatitis who receive medical attention at “Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado” (Institute for Social Security and Social Services for State Workers, better known as ISSSTE), as well as the main variables associated with it.Methods: A multicenter, retrospective cohort study. Clinical records of patients with moderate to severe atopic dermatitis were reviewed and a multivariate analysis was designed by using a generalized linear model.Results: 65 patients were included; 41 of them (63.07 %) had moderate atopic dermatitis, and 24 (36.92 %) had severe AD; 39 (60 %) of them were female patients. In groups with severe atopic dermatitis, statistically significant differences were observed in matters of the duration of the evolution of the disease, comorbidities, intense pruritus, and depression. The average annual cost of medical care for patients with moderate atopic dermatitis was 1527 ± 623 USD, and for patients with severe atopic dermatitis the cost was 9487 ± 8990 USD. Significant differences were observed in dermatology consultations, referrals, laboratory and diagnostic studies, and the number of drugs prescribed by physicians. With the multivariate analysis, it was identified that the highest cost was presented by severe patients (p = 0.0001) who were younger and had comorbidities, along with diagnosis of depression.Conclusions: The severity of atopic dermatitis, the age average, the presence of comorbidities, and the diagnosis of depression are the variables with the highest association and impact on the direct cost of medical care.